Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model

Front Public Health. 2023 Sep 6:11:1201818. doi: 10.3389/fpubh.2023.1201818. eCollection 2023.

Abstract

Objective: To systematically estimate and compare the effectiveness and cost-effectiveness of the glucagon-like peptide-1 receptor agonists (GLP-1RAs) approved in China and to quantify the relationship between the burden of diabetic comorbidities and glycosylated hemoglobin (HbA1c) or body mass index (BMI).

Methods: To estimate the costs (US dollars, USD) and quality-adjusted life years (QALY) for six GLP-1RAs (exenatide, loxenatide, lixisenatide, dulaglutide, semaglutide, and liraglutide) combined with metformin in the treatment of patients with type 2 diabetes mellitus (T2DM) which is inadequately controlled on metformin from the Chinese healthcare system perspective, a discrete event microsimulation cost-effectiveness model based on the Chinese Hong Kong Integrated Modeling and Evaluation (CHIME) simulation model was developed. A cohort of 30,000 Chinese patients was established, and one-way sensitivity analysis and probabilistic sensitivity analysis (PSA) with 50,000 iterations were conducted considering parameter uncertainty. Scenario analysis was conducted considering the impacts of research time limits. A network meta-analysis was conducted to compare the effects of six GLP-1RAs on HbA1c, BMI, systolic blood pressure, and diastolic blood pressure. The incremental net monetary benefit (INMB) between therapies was used to evaluate the cost-effectiveness. China's per capita GDP in 2021 was used as the willingness-to-pay threshold. A generalized linear model was used to quantify the relationship between the burden of diabetic comorbidities and HbA1c or BMI.

Results: During a lifetime, the cost for a patient ranged from USD 42,092 with loxenatide to USD 47,026 with liraglutide, while the QALY gained ranged from 12.50 with dulaglutide to 12.65 with loxenatide. Compared to exenatide, the INMB of each drug from highest to lowest were: loxenatide (USD 1,124), dulaglutide (USD -1,418), lixisenatide (USD -1,713), semaglutide (USD -4,298), and liraglutide (USD -4,672). Loxenatide was better than the other GLP-1RAs in the base-case analysis. Sensitivity and scenario analysis results were consistent with the base-case analysis. Overall, the price of GLP-1RAs most affected the results. Medications with effective control of HbA1c or BMI were associated with a significantly smaller disease burden (p < 0.05).

Conclusion: Loxenatide combined with metformin was identified as the most economical choice, while the long-term health benefits of patients taking the six GLP-1RAs are approximate.

Keywords: cost-effectiveness; discrete event micro-simulation model; effectiveness; glucagon-like peptide-1 receptor agonists; type 2 diabetes mellitus.

Publication types

  • Comparative Study
  • Meta-Analysis

MeSH terms

  • Body Mass Index
  • Comorbidity
  • Computer Simulation
  • Cost of Illness
  • Cost-Benefit Analysis
  • Cost-Effectiveness Analysis
  • Diabetes Mellitus, Type 2* / blood
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / economics
  • Drug Therapy, Combination
  • East Asian People
  • Exenatide
  • Glucagon-Like Peptide 1* / analogs & derivatives
  • Glucagon-Like Peptide-1 Receptor* / agonists
  • Glycated Hemoglobin* / analysis
  • Glycemic Control / methods
  • Humans
  • Hypoglycemic Agents* / economics
  • Hypoglycemic Agents* / therapeutic use
  • Liraglutide
  • Metformin*
  • Quality-Adjusted Life Years
  • Treatment Outcome

Substances

  • dulaglutide
  • Exenatide
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin
  • Hypoglycemic Agents
  • Liraglutide
  • lixisenatide
  • Metformin
  • semaglutide

Supplementary concepts

  • Chinese people